Mediaboss Marketing

St. Jude deliberately designed its campus and culture to spark connections between clinicians and scientists, giving drug discovery projects the greatest chance of real-world success. Scientists and clinicians translate laboratory breakthroughs into novel treatment options for patients at St. Judeand around the world.

Small molecule discovery: From high-throughput screening to tailored molecular design, investigators in the Department of Chemical Biology and Therapeutics pursue the full spectrum of approaches to identify small molecules with excellent therapeutic potential.

Vaccines, gene therapy and other biologics: Many effective therapies involve biological products. To serve our patients and investigators, St. Jude was the first pediatric cancer research center in the United States to open an on-site Good Manufacturing Practice (GMP) facility. This facility plays a critical role in moving promising discoveries fromSt. Judelaboratories into the hospital's clinics, ensuring that biopharmaceuticals and other biological products for patient use are manufactured in accordance with strict federal regulations.

Pharmacogenomics: Scientists and clinicians at St. Jude have pioneered pharmacogenomics discovery research and clinical implementation since the early 1990s. Research has uncovered pharmacogenetic variants influencing common anti-cancer drugs. These efforts have enabled the clinical implementation of pharmacogenomics, shifting the precision medicine paradigm in pediatric oncology.

The following drug discovery experts are available to offer hands-on expertise in developing therapeutics and biopharmaceuticals.

To schedule an interview, emailmedia@stjude.org.

Read the original:
Drug Development Experts and Information for Media - St. Jude ... - St. Jude Children's Research Hospital